|
MammaPrint is a diagnostic test to assess the risk that a breast tumor will metastasize to other parts of the body. This helps physicians determine whether or not each patient will benefit from chemotherapy. MammaPrint is part of the Symphony Suite of breast cancer decision support tests marketed by Agendia. MammaPrint is based on the Amsterdam 70-gene breast cancer gene signature. It uses paraffin embedded or fresh tissue for the microarray analysis. In February 2007, the U.S. Food and Drug Administration (FDA) cleared the MammaPrint test for use in the U.S. for lymph node negative breast cancer patients of all ages, ER negative or ER positive, with tumors of less than 5 cm. The cost of the assay in the U.S. is $4,200. In Europe, the test costs EUR 2675. ==Sampling technique== There are two specimen types that can be submitted: * Formalin-fixed paraffin-embedded tissue block or 10 unstained slides with a 5 micron section on each slide Must contain at least 30% invasive tumor or * Fresh specimen Core needle biopsies or tissue taken from a surgical specimen. If submitting a fresh specimen, the sample must be at least 3x3mm (tic-tac size) preserved in RNARetain®. Maximum side dimension should not exceed 5 mm to allow adequate penetration of RNARetain 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「MammaPrint」の詳細全文を読む スポンサード リンク
|